CD80 Antibody and MTX Co-Engineered Extracellular Vesicles Targets CD80+ Macrophages to Suppress Inflammation and Alleviate Chronic Inflammatory Diseases

Jianhua Yang, H. Zhang, Wenzhe Wang, Qianqian Yin, Xiaoning He, Dan Tao, Haibo Wang, Wenhao Liu, Yiming Wang, Zhiwei Dong, Xin Chen, Bei LiInternational Journal of Nanomedicine 2025 · DOI

Abstract

In this study, the anti-CD80-MTX-Evs demonstrated significant therapeutic effects in both rheumatoid arthritis and periodontitis models through a triple mechanism: reducing CD80<sup>+</sup> macrophage population, enhancing Treg cell differentiation, and suppressing Th1 cell development. Overall, this study presents an innovative strategy for resolving inflammation within chronic inflammatory diseases.

Introduction

Chronic inflammatory diseases, such as rheumatoid arthritis (RA) and periodontitis (PD), are characterized by a persistent breakdown in immune homeostasis. Pro-inflammatory macrophages, particularly those expressing the CD80 surface marker, serve as primary mediators of tissue and bone destruction. While methotrexate (MTX) remains a cornerstone of treatment, its systemic toxicity often limits its clinical utility due to side effects in the liver, kidneys, and gastrointestinal tract.

To address this, researchers have developed "smart" extracellular vesicles (EVs) co-engineered with CD80 antibodies and MTX. These engineered vesicles specifically target pro-inflammatory macrophages to reprogram the local immune environment from a state of chronic destruction to one of immune tolerance.

Methodology

The study employed a bioengineering approach to create a targeted delivery vehicle:

  • EV Source: Extracellular vesicles were harvested from human umbilical cord mesenchymal stem cells (hUCMSCs), chosen for their low immunogenicity and inherent anti-inflammatory properties.
  • Surface Engineering: A lipid-anchoring method (DSPE-PEG-Anti-CD80) was used to graft CD80 antibodies onto the EV membrane, enabling precise targeting of CD80+ macrophages.
  • Drug Loading: MTX was incorporated into the EVs during cellular production.
  • Validation: The resulting anti-CD80-MTX-EVs were characterized using Transmission Electron Microscopy (TEM) and Nanoparticle Tracking Analysis (NTA), showing an average size of 350–450 nm.
  • Disease Models: Therapeutic efficacy was evaluated in mouse models of Collagen-Induced Arthritis (CIA) and ligature-induced Periodontitis (PD).

Key Results and Insights

The anti-CD80-MTX-EVs demonstrated a "triple mechanism" of action: reducing pro-inflammatory CD80+ macrophages, upregulating TGF-β to promote Regulatory T cell (Treg) differentiation, and suppressing Th1 cell development. By targeting the interaction between innate (macrophages) and adaptive (T cells) immunity, the therapy restores the body's natural ability to resolve inflammation.

In the CIA model, the treatment significantly reduced clinical scores and joint injury. In the PD model, it effectively prevented alveolar bone loss. Flow cytometry analysis confirmed the shift in immune cell populations across various tissues.

Figure E: Flow cytometry analysis of CD80+ and CD86+ macrophage populations in peripheral lymph nodes (pLN) following treatment.

As shown in Figure E, the treatment significantly reduced the percentage of pro-inflammatory CD80+ macrophages in the peripheral lymph nodes. Similar trends in immune reprogramming were observed systemically.

Figure F: Analysis of macrophage populations in the spleen, showing significant reduction in CD86+ pro-inflammatory markers.

Figure F illustrates the impact on splenic macrophage populations, where a significant reduction in the CD86+ marker further supports the systemic immune-reprogramming capabilities of the engineered EVs.

Conclusion and Future Directions

This study provides a compelling proof-of-concept for using engineered biological vesicles as precision tools to resolve chronic inflammation. Future work will focus on the scalability of EV production and investigating the cellular specificity of CD80 targeting, as CD80 is also expressed on dendritic and B cells. Detailed pharmacokinetic studies are also required before clinical translation to ensure long-term safety and efficacy in humans.

Summary updated

Abstract

In this study, the anti-CD80-MTX-Evs demonstrated significant therapeutic effects in both rheumatoid arthritis and periodontitis models through a triple mechanism: reducing CD80<sup>+</sup> macrophage population, enhancing Treg cell differentiation, and suppressing Th1 cell development. Overall, this study presents an innovative strategy for resolving inflammation within chronic inflammatory diseases.
BibTeX
@article{yang2025cd,
  author = {Jianhua Yang and H. Zhang and Wenzhe Wang and Qianqian Yin and Xiaoning He and Dan Tao and Haibo Wang and Wenhao Liu and Yiming Wang and Zhiwei Dong and Xin Chen and Bei Li},
  title = {{CD80 Antibody and MTX Co-Engineered Extracellular Vesicles Targets CD80+ Macrophages to Suppress Inflammation and Alleviate Chronic Inflammatory Diseases}},
  journal = {International Journal of Nanomedicine},
  year = {2025},
  doi = {10.2147/ijn.s517357},
}
Figure